{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:43:54Z","timestamp":1786718634261,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Indian Acad Neurol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/aian.aian_263_18","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T05:31:00Z","timestamp":1545802260000},"page":"6","source":"Crossref","is-referenced-by-count":15,"title":["Innovations in acute stroke reperfusion strategies"],"prefix":"10.4103","volume":"22","author":[{"given":"MV","family":"Padma Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VenugopalanY","family":"Vishnu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0972-2327.248507-1","doi-asserted-by":"crossref","unstructured":"Bhaskar S, Stanwell P, Cordato D, Attia J, Levi C. Reperfusion therapy in acute ischemic stroke: Dawn of a new era? BMC Neurol 2018;18:8.","DOI":"10.1186\/s12883-017-1007-y"},{"key":"key-10.4103\/0972-2327.248507-2","first-page":"1581","volume-title":"Tissue plasminogen activator for acute ischemic stroke","author":"National","year":"1995","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-3","first-page":"1017","volume-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke","author":"Hacke","year":"1995","journal-title":"The European Cooperative Acute Stroke Study (ECASS) JAMA"},{"key":"key-10.4103\/0972-2327.248507-4","first-page":"223","volume-title":"Thrombolysis at 3-4.5 hours after acute ischemic stroke onset \u2013 Evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry","author":"Shobha","year":"2011","journal-title":"Cerebrovasc Dis"},{"key":"key-10.4103\/0972-2327.248507-5","first-page":"866","volume-title":"Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: An updated analysis from SITS-ISTR","author":"Ahmed","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0972-2327.248507-6","first-page":"1929","volume-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials","author":"Emberson","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/0972-2327.248507-7","first-page":"385","volume-title":"Implications of ECASS III error on emergency department treatment of ischemic stroke","author":"Shy","year":"2014","journal-title":"J Emerg Med"},{"key":"key-10.4103\/0972-2327.248507-8","doi-asserted-by":"crossref","unstructured":"Alper BS, Malone-Moses M, McLellan JS, Prasad K, Manheimer E. Thrombolysis in acute ischaemic stroke: Time for a rethink? BMJ 2015;350:h1075.","DOI":"10.1136\/bmj.h1075"},{"key":"key-10.4103\/0972-2327.248507-9","first-page":"811","volume-title":"The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study.Thromblytic therapy in acute ischemic stroke study investigators","author":"Clark","year":"2000","journal-title":"Stroke"},{"key":"key-10.4103\/0972-2327.248507-10","doi-asserted-by":"crossref","unstructured":"Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999;282:2019-26.","DOI":"10.1001\/jama.282.21.2019"},{"key":"key-10.4103\/0972-2327.248507-11","first-page":"2352","volume-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial","author":"IST-3","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/0972-2327.248507-12","first-page":"2313","volume-title":"Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke","author":"Anderson","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-13","first-page":"2389","volume-title":"Finding the right t-PA dose for Asians with acute ischemic stroke","author":"Sila","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-14","first-page":"1328","volume-title":"Low-dose vs.standard-dose alteplase for patients with acute ischemic stroke: Secondary analysis of the ENCHANTED randomized clinical trial","author":"Wang","year":"2017","journal-title":"JAMA Neurol"},{"key":"key-10.4103\/0972-2327.248507-15","doi-asserted-by":"crossref","unstructured":"Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr., Starr M, Mejilla J, et al. Effect of alteplase vs. aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: The PRISMS randomized clinical trial. JAMA 2018;320:156-66.","DOI":"10.1001\/jama.2018.8496"},{"key":"key-10.4103\/0972-2327.248507-16","doi-asserted-by":"crossref","unstructured":"Powers WJ. Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far? JAMA 2018;320:141-3.","DOI":"10.1001\/jama.2018.8511"},{"key":"key-10.4103\/0972-2327.248507-17","first-page":"611","volume-title":"MRI-guided thrombolysis for stroke with unknown time of onset","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-18","first-page":"260","volume-title":"European cooperative acute stroke study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND","author":"Amiri","year":"2016","journal-title":"Int J Stroke"},{"key":"key-10.4103\/0972-2327.248507-19","unstructured":"European Stroke Journal. Available from: https:\/\/www.eso-conference.org\/2018\/scientific-information\/european-stroke-journal-(esj)#. Wx46Fy2B10s. [Last accessed on 2018 Jun 11]."},{"key":"key-10.4103\/0972-2327.248507-20","first-page":"3670","volume-title":"A faster-acting and more potent form of tissue plasminogen activator","author":"Keyt","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/0972-2327.248507-21","first-page":"1069","volume-title":"Intravenous tenecteplase in acute ischemic stroke: An updated review","author":"Behrouz","year":"2014","journal-title":"J Neurol"},{"key":"key-10.4103\/0972-2327.248507-22","first-page":"607","volume-title":", Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators.A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke","author":"Haley","year":"2005","journal-title":"Stroke"},{"key":"key-10.4103\/0972-2327.248507-23","first-page":"275","volume-title":"Tenecteplase versus alteplase for acute ischemic stroke","author":"Gonz\u00e1lez","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-24","first-page":"368","volume-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): A phase 2, randomised, open-label, blinded endpoint study","author":"Huang","year":"2015","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0972-2327.248507-25","first-page":"781","volume-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0972-2327.248507-26","first-page":"762","volume-title":"NOR-TEST-ing tenecteplase in acute ischaemic stroke","author":"Anderson","year":"2017","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0972-2327.248507-27","first-page":"707","volume-title":", Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB\/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial","author":"Haley","year":"2010","journal-title":"Stroke"},{"key":"key-10.4103\/0972-2327.248507-28","first-page":"1099","volume-title":"A randomized trial of tenecteplase versus alteplase for acute ischemic stroke","author":"Parsons","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-29","doi-asserted-by":"crossref","unstructured":"Thelengana A, Radhakrishnan DM, Prasad M, Kumar A, Prasad K. Tenecteplase versus alteplase in acute ischemic stroke: Systematic review and meta-analysis. Acta Neurol Belg 2018.","DOI":"10.1007\/s13760-018-0933-9"},{"key":"key-10.4103\/0972-2327.248507-30","unstructured":"Venugopalan V, Basheer A, Kirubakaran R, Srivastava P. Tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours. PROSPERO 2018 CRD42018098721. Available from: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42018098721. [Last accessed on 2018 Aug]."},{"key":"key-10.4103\/0972-2327.248507-31","first-page":"387","volume-title":"Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: Results of two open-label, multicenter trials","author":"Ramakrishnan","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"key-10.4103\/0972-2327.248507-32","first-page":"3020","volume-title":"2015 American Heart Association\/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","author":"Powers","year":"2015","journal-title":"Stroke"},{"key":"key-10.4103\/0972-2327.248507-33","first-page":"1723","volume-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials","author":"Goyal","year":"2016","journal-title":"Lancet"},{"key":"key-10.4103\/0972-2327.248507-34","first-page":"11","volume-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","author":"Nogueira","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-35","first-page":"708","volume-title":"Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging","author":"Albers","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-36","first-page":"1161","volume-title":"Thrombectomy 6 to 24 hours after stroke","author":"Jovin","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-37","first-page":"1849","volume-title":"Thrombectomy for stroke with selection by perfusion imaging","author":"Vinny","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.248507-38","first-page":"768","volume-title":"Late window paradox","author":"Albers","year":"2018","journal-title":"Stroke"},{"key":"key-10.4103\/0972-2327.248507-39","first-page":"708","volume-title":"Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue","author":"Lansberg","year":"2015","journal-title":"Neurology"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:37:45Z","timestamp":1786714665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_263_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"alternative-id":["248507"],"URL":"https:\/\/doi.org\/10.4103\/aian.aian_263_18","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}